Model Medicines raises $4M to develop new therapies

By The Science Advisory Board staff writers

November 3, 2021 -- Model Medicines has raised $4.1 million to bolster its therapeutic pipeline for challenging and rare diseases in oncology, infectious diseases, and gastric disorders.

Funds will be used to advance the company's drug development programs, including advancing in vitro validated candidates to preclinical proof of concept and its lead asset, MDL-001, an oral infectious disease drug candidate, toward an investigational new drug submission.

The oversubscribed financing round received participation from 8VC, Irving Investors, Particle X, and Nex Cubed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.